PULSE BIOSCIENCES, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $PLSE in the last 7 days.
Teplitsky Liane Rae (Chief Operating Officer) purchased 2,070 shares of PULSE BIOSCIENCES, INC. (PLSE) at an average of $48.29 ($48.24–$48.35) across 2 trades over 2026-08-26 to 2026-08-28.
Stock indices fluctuated as chipmakers rose while software companies declined. S&P 500 Q2 earnings are tracking at +32% growth, with AI infrastructure contributing 60%. Sandisk (SNDK) led gains, up +10%, while Datadog (DDOG) led losses, down -3%. EyePoint (EYPT) dropped -71% after a failed trial. Constellation Brands (STZ) fell -5% after Berkshire Hathaway sold its stake.
Wall Street analysts issued several rating changes. Deutsche Bank upgraded PennyMac Mortgage Investment Trust (PMT) to Buy, keeping a $12 target. Northland Capital Markets upgraded Astera Labs (ALAB) to Outperform with a $350 target. Wells Fargo upgraded Okta (OKTA) to Overweight and raised its target to $180 from $150.
Recent PLSE coverage spans market movers, financial news and earnings.
In the last 30 days, PLSE insiders filed 2 SEC Form 4 transactions — 2 purchases ($100K) and no sales. The most active reporter was Teplitsky Liane Rae, Chief Operating Officer, with 2 filings.
Small insider purchase may signal confidence but size is modest; limited immediate price impact.
New coverage with a defined target can attract incremental speculative and value-seeking flows to PLSE.
Wall Street analysts issued several rating changes. Deutsche Bank upgraded PennyMac Mortgage Investment Trust (PMT) to Buy, keeping a $12 target. Northland Capital Markets upgraded Astera Labs (ALAB) to Outperform with a $350 target. Wells Fargo upgraded Okta (OKTA) to Overweight and raised its target to $180 from $150.
Clinical execution and financing updates improve near-term visibility for regulatory submissions, but dilution risk remains tied to the ATM program.
The filing discloses a new at-the-market style equity issuance program, increasing near-term dilution overhang risk.
alphai scores every news story that mentions PLSE with an AI model for sentiment and relevance, and aggregates insider trades from PULSE BIOSCIENCES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Teplitsky Liane Rae (Chief Operating Officer) purchased 2,070 shares of PULSE BIOSCIENCES, INC. (PLSE) at an average of $48.29 ($48.24–$48.35) across 2 trades over 2026-08-26 to 2026-08-28.
1 min readStock indices fluctuated as chipmakers rose while software companies declined. S&P 500 Q2 earnings are tracking at +32% growth, with AI infrastructure contributing 60%. Sandisk (SNDK) led gains, up +10%, while Datadog (DDOG) led losses, down -3%. EyePoint (EYPT) dropped -71% after a failed trial. Constellation Brands (STZ) fell -5% after Berkshire Hathaway sold its stake.
6 min readWall Street analysts issued several rating changes. Deutsche Bank upgraded PennyMac Mortgage Investment Trust (PMT) to Buy, keeping a $12 target. Northland Capital Markets upgraded Astera Labs (ALAB) to Outperform with a $350 target. Wells Fargo upgraded Okta (OKTA) to Overweight and raised its target to $180 from $150.
2 min readPulse Biosciences (PLSE) reported Q2 2026 revenue of $434,000 and GAAP net loss of $24.7 million. Cash and equivalents rose to $101.6 million by June 30, 2026 after $57.5 million in ATM proceeds. NANOPULSE-AF enrollment exceeded halfway with early October completion target; CE Mark for the catheter expected in 2H 2026.
7 min readPULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 6, 2026, Pulse Biosciences, Inc. (the “Company”) entered into an equity distribution agreement (the “Sales Agreement”) with Mizuho Securities USA LLC (“Mizuho”) as sales agent, pursuant to which the Company may offer
4 min readPULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results HAYWARD, California [Business Wire] — August 6, 2026. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-P
7 min readBiotech shares hit 52-week highs on Aug. 3-4, 2026, led by catalysts including upcoming quarterly reports and clinical-trial updates. AngioDynamics (ANGO) reached $15.41, citing FDA clearance for its RELIEF study and FY2026 net sales of $320.2 million. Anika (ANIK) hit $21.11 after Q2 revenue rose to $32.6 million. Pulse (PLSE) rose to $38.29 ahead of Aug. 6 results; Eloxx (ELOX) and Yarrow (YARW) also reached highs.
7 min readBiotech shares hit 52-week highs on July 28, 2026. Incyte (INCY) rose over 9% to $132.58 after Q2 revenue of $1.67B, up 38% year over year, and raised full-year net sales guidance to $5.13B-$5.26B. Pulse Biosciences (PLSE) gained over 8% to $36.29. Other climbers included Shoulder Innovations (SI), Bioventus (BVS), and LB Pharmaceuticals (LBRX).
4 min readPulse Clean Energy said it reached financial close on two UK battery energy storage projects in Plymouth and Dowlais, under construction. The projects received Technology Performance Insurance from Ariel Green, designed to provide up to 13 years of coverage to support financing and long-term performance risk management. Aon advised as broker and Eversheds Sutherland as legal adviser.
3 min readPULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. plse20260607c_8k.htm false 0001625101 0001625101 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Rep
2 min read
